Galectin Therapeutics Stock News

NORCROSS, Ga., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be pa

Results from the phase 3 NAVIGATE study using Belapectin for the treatment of patients with NASH Cirrhosis without esophageal varices are expected in Q1 of 2024. If the primary endpoint of the phase 3

NORCROSS, Ga., May 23, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be pres

WASHINGTON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the Global Non-Alcoholic Steatohepatitis (NASH) Market finds that growing demand for ideal NASH therapeutics is expediting market growth. Primarily driven by increasing pharmaceutical Research and Development (R&D) expenditure, the total global Non-Alcoholic Steatohepatitis (NASH) Market is estimated to reach USD 21,879 Million by 2028, up from USD 1,569 Million in 2021, at a Compound Annual Growth Rate (CAGR) of 60.4%. Furthermore, the escalating obese population across the globe is also anticipated to augment the growth of the Global Non-Alcoholic Steatohepatitis (NASH) Market, states Vantage Market Research, in a report, titled " Non Alcoholic Steatohepatitis (NASH) Market by Drug Type (Vitamin E & Pioglitazone, Ocaliva, Elafibranor, Selonsertib), by Sales Channel (Hospital Pharmacy, Online Provider, Retail Pharmacy), by Region (North America, Latin America, Europe, Asia Pacific) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)" .

NORCROSS, Ga., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT ), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright BioConnect Conference being held virtually January 10-13, 2022. Mr. Joel Lewis, President and Chief Executive Officer, and Dr. Pol F. Boudes, Chief Medical Officer, will be presenting on behalf of the Company. A webcast of this presentation will be available on the "Investor Relations" section under "Events and Presentations" of the Company''s website, https://investor.galectintherapeutics.com , at Full story available on Benzinga.com

NORCROSS, Ga., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be par

NAVIGATE clinical trial in NASH cirrhosis now underway in all countries originally selected; full enrollment expected by mid-2022

Wall Street analysts expect Galectin Therapeutics Inc. (NASDAQ:GALT) to post earnings of ($0.19) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Galectin Therapeutics earnings. Galectin Therapeutics posted earnings per share of ($0.14) in the same quarter last year, which suggests a negative year-over-year growth rate of 35.7%. The []

Galectin Therapeutics Inc. (NASDAQ:GALT) Director Kevin D. Freeman bought 5,000 shares of Galectin Therapeutics stock in a transaction on Monday, December 6th. The stock was acquired at an average cost of $2.34 per share, with a total value of $11,700.00. The purchase was disclosed in a document filed with the SEC, which is available at []

Analysts predict that Galectin Therapeutics Inc. (NASDAQ:GALT) will announce earnings of ($0.19) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Galectin Therapeutics earnings. Galectin Therapeutics reported earnings of ($0.14) per share during the same quarter last year, which would indicate a negative year over year growth rate of []

Equities research analysts expect Galectin Therapeutics Inc. (NASDAQ:GALT) to post earnings of ($0.19) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Galectin Therapeutics earnings. Galectin Therapeutics posted earnings of ($0.14) per share in the same quarter last year, which would indicate a negative year over year growth rate []

Board approves exploration of a Company-sponsored belapectin oncology program complementing our ongoing NASH cirrhosis program

NORCROSS, Ga., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that it will present six

NORCROSS, Ga., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be par